Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989 Jun;27(6):757-61.
doi: 10.1111/j.1365-2125.1989.tb03437.x.

The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers

Affiliations
Clinical Trial

The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers

D J Webb et al. Br J Clin Pharmacol. 1989 Jun.

Abstract

1. The effect of the K+ channel opening drug cromakalim on forearm blood flow during direct infusion into the brachial artery, and on the size of noradrenaline preconstricted hand veins during infusion directly into the vein, was studied in eight healthy volunteers. 2. Cromakalim (0.01-10.0 micrograms min-1) produced a dose-dependent increase in blood flow in the infused forearm, from 5.4 +/- 2.5 to 15.1 +/- 7.3 ml 100 ml-1 forearm min-1 at 10 micrograms min-1 (P less than 0.001). The half-time of offset of its action was 30 min. There was no change in blood flow in the non-infused forearm. 3. There was no increase in the size of noradrenaline pre-constricted dorsal veins during local infusion of cromakalim (0.001-1.0 microgram min-1). Glyceryl trinitrate (0.4 microgram min-1) however, completely reversed the constriction to noradrenaline (P less than 0.001). 4. The clear arterioselectivity of cromakalim, as with other members of this new class of drug, accords with the dependency of venoconstriction on receptor-operated, rather than potential-operated mechanisms which are of importance in resistance vessels. With this haemodynamic profile cromakalim may prove of value in the treatment of arterial hypertension.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Pharmacol. 1988 Nov;95(3):741-52 - PubMed
    1. J Pharmacol Exp Ther. 1988 Jun;245(3):751-60 - PubMed
    1. Trends Pharmacol Sci. 1988 Jan;9(1):21-8 - PubMed
    1. J Physiol. 1953 Jul;121(1):1-27 - PubMed
    1. Clin Sci Mol Med. 1974 Aug;47(2):189-92 - PubMed

Publication types

LinkOut - more resources